Kristina Kirschner
@krikirschner.bsky.social
92 followers 110 following 22 posts
Associate Professor interested in how aging drives hematopoietic stem cell dynamics at Mayo Clinic, MN https://www.mayo.edu/research/labs/stem-cell-aging-cancer/overview
Posts Media Videos Starter Packs
krikirschner.bsky.social
Happy to have been invited to guest edit this exciting special issue. Check it out!
isehsociety.bsky.social
‪The Special Issue New Culture Methods in Experimental Hematology covers novel co-culture approaches and mechanobiological efforts driving innovation. Reach the issue from guest editor @krikirschner.bsky.social‬ only on www.exphem.org/content/new_...
krikirschner.bsky.social
I’m excited to speak at the #EHASWG Scientific Workshop on Stem Cells and Aging in Barcelona from November 13-15, 2025, and immerse myself in the field of hematopoietic stem cell aging. Submit your abstract for a chance to join me! More info: eha.fyi/SWG_HSC_ft
EHA-SWG Scientific Workshop on From Aging Hematopoietic Stem Cells to Age-related Diseases: Opportunities for Intervention - The European Hematology Association (EHA)
eha.fyi
Reposted by Kristina Kirschner
isehsociety.bsky.social
This week on #SimplyBlood 🩸 we're highlighting articles in the ExpHem Special Issue: New Culture Methods in Experimental Hematology from guest editor @krikirschner.bsky.social Read the highlights on www.simplyblood.org.
krikirschner.bsky.social
Great kick off at the annual Alliance for Healthy Aging Conference hosted by the Mayo Clinic Kogod Centre on Aging Center in Jacksonville Florida with a keynote by @adamsbioaging.bsky.social
Reposted by Kristina Kirschner
richardsever.bsky.social
Big news: we are setting up a new non-profit organization to run bioRxiv and medRxiv. It's called openRxiv [no it's not a new preprint server; it's dedicated organization to oversee the servers] openrxiv.org 1/n
Homepage - openRxiv
openRxiv is an independent non-profit, the new organizational home for bioRxiv and medRxiv, enabling researchers to instantly share groundbreaking findings with the global scientific community.
openrxiv.org
krikirschner.bsky.social
Our framework enables more accurate prediction of CH's clinical impact, moving us closer to personalized risk assessment and potential intervention strategies.
krikirschner.bsky.social
MACS120 outperformed traditional measurements (like variant allele frequency) in predicting mortality risk and showed increased correlations with the speed of change in blood markers like lymphocyte and albumin levels.
krikirschner.bsky.social
Considering these factors, we developed MACS120 - a novel metric that combines mutation fitness and acquisition timing to predict maximum clone size a mutation will reach over a lifetime.
krikirschner.bsky.social
Third, we discovered a strong correlation between mutation timing, or age at time of mutation acquisition (ATMA), and fitness. Higher fitness mutations tend to appear later in life - possibly due to declining quality control mechanisms with age.
krikirschner.bsky.social
Similarly, mutations can have different fitness effects depending on what other mutations are present in the same clone. For example, ASXL1 mutations have higher fitness when co-occurring with SRSF2 than with TET2.
krikirschner.bsky.social
Second, we found that clonal coexistence matters! Mutations don't grow in isolation - when multiple clones are present in the same person, they alter each other's overall contribution to the production of blood cells.
krikirschner.bsky.social
First, we confirmed gene-specific fitness differences: RNA splicing mutations (like U2AF1, U2AF2) show higher fitness than epigenetic regulator mutations (like DNMT3A, TET2).
krikirschner.bsky.social
Our key insight: Three factors, mutation fitness (growth advantage), mutation timing, and clonal structure (which mutations occur together) are needed to understand the progression and clinical impact of CH.
krikirschner.bsky.social
We integrated data from 713 individuals across 3 longitudinal aging cohorts (2,341 observations total) and developed models to understand the dynamics of CH mutations over time. #CancerResearch #ClonalHematopoiesis
krikirschner.bsky.social
Clonal hematopoiesis (CH) is common in aging populations and associated with increased risk of blood cancers and other diseases. But what determines which CH mutations will progress to disease?
krikirschner.bsky.social
TUTORIAL: Our new preprint "Clinical progression of clonal hematopoiesis is determined by a combination of mutation timing, fitness, and clonal structure" is out @elatorre.bsky.social @edinunilbc.bsky.social @linusschumacher.bsky.social @biologyaging.bsky.social
www.biorxiv.org/content/10.1...
www.biorxiv.org
krikirschner.bsky.social
Great workshop on Aging and Hematology #ASH2024 pitching cell intrinsic vs cell extrinsic aging factors
krikirschner.bsky.social
Excited to be part of this amazing workshop. Thanks for organising @megvoda.bsky.social
krikirschner.bsky.social
On my way to #ASH2024 preparing for the Aging Workshop tomorrow.
krikirschner.bsky.social
Pleasure to host you as always!
krikirschner.bsky.social
Congratulations on this nice piece of work!